Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

GlaxoSmithKline and Dynavax forge immuno-inflammatory disease alliance
January 2009
SHARING OPTIONS:

LONDON—GlaxoSmithKline plc and Dynavax Technologies Corp. announced Dec. 17 their partnership to develop novel inhibitors of endosomal toll-like receptors (TLRs) for the treatment of autoimmune and inflammatory diseases such as lupus, psoriasis and rheumatoid arthritis. Under the terms of the alliance, Dynavax will receive an initial payment of $10 million and GSK will receive an exclusive option over four programs. Dynavax is also eligible to receive future potential development and commercialization milestones totaling approximately $200 million per program as well as tiered, up to double-digit royalties on sales and has retained an option to co-develop and co-promote one specified product. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.